Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.44 |
| ▸ | ITGAV | P06756 | 8/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.44 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790911 | 0.91 | NAMPT (0.49) | NAMPTITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4761797 | 0.90 | ITGB3 (0.53) | NAMPTITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4760017 | 0.88 | ITGB3 (0.54) | NAMPTITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4762284 | 0.88 | ITGB3 (0.53) | NAMPTITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4714941 | 0.86 | GRIN2B (0.39) | NAMPTITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4790307 | 0.86 | ITGB3 (0.44) | NAMPTITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4789373 | 0.86 | DPP4 (0.48) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4791386 | 0.84 | ITGB3 (0.51) | NAMPTITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL4760967 | 0.83 | NAMPT (0.48) | NAMPTITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL14222587 | 0.82 | ITGB3 (0.52) | NAMPTITGB3ITGAVITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |